RCS - Gareth W.V. Cave - Substantial RMS Shareholder Support for Dr Cave

Wam CapitalAnnouncement

22/12/2020 09:00

RNS Number : 4947J
  
Gareth Wynn Vaughan Cave
  
22 December 2020
  
 

22 DECEMBER 2020
 
Dr Gareth Cave
Remote Monitored Systems PLC ("RMS" or the "Company")
 
Private Investor support for Dr Cave's plan to vote against warrants and in favour of board changes to improve corporate governance now exceeds his own 17.7% shareholding
 
Dr Cave announces that, since his announcement yesterday, his advisers Egremont Capital Limited ("Egremont") have been overwhelmed by support from private investors concerned with the current make-up of the board and opposed to the placing with warrants announced by the Board on 18 December 2020.
 
Dr Cave has been advised by Egremont that, as at 2.00 am on 22 December 2020, it had received emails of support from 386 shareholders stating that they represented in aggregate 301.3 million ordinary shares in RMS. It is not possible to verify these holdings definitively using the share register provided by the Company, as many private investors hold shares via nominee holdings.  However, if the communications are accurate, this represents 18.7 per cent of the current voting rights of the Company. Taken with Dr Cave's holding of 17.7 per cent. there is now a substantial groundswell of shareholders opposed to the actions of the current board of directors.
 
Dr Cave commented: "I am personally delighted by the support I have received from private investors. We cannot respond individually to each email but will keep all of these supporters updated on developments. I am saddened that RMS and its advisers seem unwilling to engage with our entirely reasonable demands. If SP Angel and Peterhouse Capital listened to shareholders rather than the current board, they would be delaying this placing until better corporate governance can be put in place."
 
ENDS
 
Voting Percentage Clarification
 
According to the RNS issued by RMS on 30 November 2020 the total number of voting rights of the company in issue are 1,583,270,231. Dr Cave holds 289,645,185 ordinary shares in RMS. The percentage total used in the announcement issued on 21 December 2020 was therefore incorrect and should have been 17.7% and not 18.4%.
 
Enquiries
 
Jonathan Hall
Egremont Capital Limited
jonathan.hall@egremont.com
0203 697 9496

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAFELSWEESSEIE